 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
30 News |  |
- ||| VE202 / Vedanta Biosci
Enrollment open, Trial completion date, Trial primary completion date: VE202-002: VE202 in Patients with Mild-to-Moderate Ulcerative Colitis (clinicaltrials.gov) - May 24, 2023
P2, N=100, Recruiting, Sponsor: Vedanta Biosciences, Inc.
Not yet recruiting --> Recruiting | Trial completion date: Feb 2025 --> Nov 2025 | Trial primary completion date: Jun 2024 --> Jul 2025
- || VE202 / Vedanta Biosci
Trial initiation date: VE202-002: VE202 in Patients with Mild-to-Moderate Ulcerative Colitis (clinicaltrials.gov) - Feb 28, 2023
P2, N=100, Not yet recruiting, Sponsor: Vedanta Biosciences, Inc.
Not yet recruiting --> Recruiting | Trial completion date: Feb 2025 --> Nov 2025 | Trial primary completion date: Jun 2024 --> Jul 2025 Initiation date: Jan 2023 --> May 2023
- || VE202 / Vedanta Biosci
Trial initiation date: VE202-002: VE202 in Patients with Mild-to-Moderate Ulcerative Colitis (clinicaltrials.gov) - Aug 30, 2022
P2, N=100, Not yet recruiting, Sponsor: Vedanta Biosciences, Inc.
Initiation date: Jan 2023 --> May 2023 Initiation date: Jun 2022 --> Jan 2023
- |||| VE202 / Vedanta Biosci
New P2 trial: VE202-002: VE202 in Patients with Mild-to-Moderate Ulcerative Colitis (clinicaltrials.gov) - May 11, 2022
P2, N=100, Not yet recruiting, Sponsor: Vedanta Biosciences, Inc.
- VE-202 / Vedanta Biosci
DURABLE COLONIZATION OF THE RATIONALLY DESIGNED LIVE BIOTHERAPEUTIC PRODUCTS VE202 AND VE818 IN HEALTHY VOLUNTEERS (20AB - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_3620;
Dose duration was an important driver of strain persistence in the long-term, with the highest number of strains colonizing across the acute, durable, and long-term sampling periods. Conclusion VE202 and VE818 were well tolerated in subjects and robustly colonized healthy volunteers after vancomycin pre-treatment.
- VE-202 / Vedanta Biosci
[VIRTUAL] VE202 - Hepatobiliary Surgery I () - Oct 9, 2020 - Abstract #ACSCLINCON2020ACS_CLINCON_1968;
- VE-202 / Vedanta Biosci
[VIRTUAL] TREATMENT OF ADULTS WITH THE CLOSTRIDIA STRAIN LIVE BIOTHERAPEUTIC PRODUCT VE202 RESULTS IN SUSTAINED AND DURABLE COLONIZATION OF THE HEALTHY HUMAN GUT (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_4540;
P1
Dense longitudinal sampling and inclusion of placebo controls employed in this study demonstrate that patterns of colonization dynamics correlate with dose and are influenced by antibiotic pre-treatment. Unexpectedly, placebo antibiotic pre-treated subjects co-housed with active drug treated subjects also demonstrated low level VE202 strain specific colonization although at significantly lower RA levels.
- VE-202 / Vedanta Biosci
[VIRTUAL] TREATMENT OF ADULTS WITH THE CLOSTRIDIA STRAIN LIVE BIOTHERAPEUTIC PRODUCT VE202 RESULTS IN SUSTAINED AND DURABLE COLONIZATION OF THE HEALTHY HUMAN GUT (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_2564;
P1
Dense longitudinal sampling and inclusion of placebo controls employed in this study demonstrate that patterns of colonization dynamics correlate with dose and are influenced by antibiotic pre-treatment. Unexpectedly, placebo antibiotic pre-treated subjects co-housed with active drug treated subjects also demonstrated low level VE202 strain specific colonization although at significantly lower RA levels.
- VE-202 / Vedanta Biosci
[VIRTUAL] TREATMENT OF ADULTS WITH THE CLOSTRIDIA STRAIN LIVE BIOTHERAPEUTIC PRODUCT VE202 RESULTS IN SUSTAINED AND DURABLE COLONIZATION OF THE HEALTHY HUMAN GUT (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_580;
P1
Dense longitudinal sampling and inclusion of placebo controls employed in this study demonstrate that patterns of colonization dynamics correlate with dose and are influenced by antibiotic pre-treatment. Unexpectedly, placebo antibiotic pre-treated subjects co-housed with active drug treated subjects also demonstrated low level VE202 strain specific colonization although at significantly lower RA levels.
- VE-202 / J&J, Vedanta Biosci
HUMAN-DERIVED CLOSTRIDIUM VE202 STRAINS REDUCE ENTEROBACTERIACEAE AND FUSOBACTERIA AND REVERSE EXPERIMENTAL COLITIS INDUCED BY HUMAN GUT MICROBIOTA () - May 4, 2020 - Abstract #DDW2020DDW_6467;
In addition, VE202 treatment is consistently effective for different human donor microbiota in vivo and in vitro. These results provide a rationale and target for therapeutic use of rationally selected resident protective bacterial cocktails in IBD patients.
- | VE202 / Vedanta Biosci
Trial completion: A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants (clinicaltrials.gov) - Mar 25, 2020
P1, N=33, Completed, Sponsor: Janssen Research & Development, LLC
These results provide a rationale and target for therapeutic use of rationally selected resident protective bacterial cocktails in IBD patients. Active, not recruiting --> Completed
- | VE202 / Vedanta Biosci
Trial completion: A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants (clinicaltrials.gov) - Jan 14, 2020
P1, N=74, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- VE-202 / J&J, Vedanta Biosciences
HUMAN-DERIVED CLOSTRIDIUM VE202 STRAINS REDUCE ENTEROBACTERIACEAE AND FUSOBACTERIA AND REVERSE EXPERIMENTAL COLITIS INDUCED BY HUMAN GUT MICROBIOTA (Exhibit Hall 1 - Austin Convention Center) - Dec 21, 2019 - Abstract #CCCongress2020CCCONGRESS_280;
In addition, VE202 treatment is consistently effective for different human donor microbiota in vivo and in vitro. These results provide a rationale and target for therapeutic use of rationally selected resident protective bacterial cocktails in IBD patients.
- | VE202 / Vedanta Biosci
Enrollment closed: A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants (clinicaltrials.gov) - Oct 16, 2019
P1, N=33, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
These results provide a rationale and target for therapeutic use of rationally selected resident protective bacterial cocktails in IBD patients. Recruiting --> Active, not recruiting
- | VE-202 / J&J, Vedanta Biosciences
Preclinical, Journal: Culture-independent Profiling of the Fecal Microbiome to Identify Microbial Species Associated with a Diarrheal Outbreak in Immunocompromised Mice. (Pubmed Central) - Oct 11, 2019
Based on these results, specific changes were made to the animal husbandry procedures for immunocompromised mice. This case report highlights the utility of culture-independent methods in laboratory animal diagnostics.
- | VE202 / Vedanta Biosci
Enrollment closed: A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants (clinicaltrials.gov) - Sep 9, 2019
P1, N=74, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
This case report highlights the utility of culture-independent methods in laboratory animal diagnostics. Recruiting --> Active, not recruiting
- | VE202 / Vedanta Biosci
Enrollment open: A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants (clinicaltrials.gov) - May 12, 2019
P1, N=46, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | VE202 / Vedanta Biosci
New P1 trial: A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants (clinicaltrials.gov) - Apr 29, 2019
P1, N=46, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | VE202 / Vedanta Biosci
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants (clinicaltrials.gov) - Feb 8, 2019
P1, N=102, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Trial completion date: May 2020 --> Dec 2019 | Trial primary completion date: May 2020 --> Dec 2019
- | VE202 / Vedanta Biosci
Enrollment open: A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants (clinicaltrials.gov) - Nov 8, 2018
P1, N=144, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: May 2020 --> Dec 2019 | Trial primary completion date: May 2020 --> Dec 2019 Not yet recruiting --> Recruiting
- | VE202 / Vedanta Biosci
New P1 trial: A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants (clinicaltrials.gov) - Oct 30, 2018
P1, N=144, Not yet recruiting, Sponsor: Janssen Research & Development, LLC